

# Giuseppe Derosa

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/8891648/giuseppe-derosa-publications-by-citations.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

335  
papers

8,413  
citations

48  
h-index

71  
g-index

378  
ext. papers

9,527  
ext. citations

4.3  
avg, IF

6.26  
L-index

#	Paper	IF	Citations
335	Sulfonylureas and their use in clinical practice. <i>Archives of Medical Science</i> , <b>2015</b> , 11, 840-8	2.9	220
334	α-Glucosidase inhibitors and their use in clinical practice. <i>Archives of Medical Science</i> , <b>2012</b> , 8, 899-906	2.9	194
333	Role of microRNAs in the Therapeutic Effects of Curcumin in Non-Cancer Diseases. <i>Molecular Diagnosis and Therapy</i> , <b>2016</b> , 20, 335-45	4.5	141
332	Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study. <i>Hypertension Research</i> , <b>2004</b> , 27, 457-64	4.7	140
331	Anti-obesity drugs: a review about their effects and their safety. <i>Expert Opinion on Drug Safety</i> , <b>2012</b> , 11, 459-71	4.1	129
330	Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial. <i>Clinical Therapeutics</i> , <b>2004</b> , 26, 744-54	3.5	127
329	Berberine on metabolic and cardiovascular risk factors: an analysis from preclinical evidences to clinical trials. <i>Expert Opinion on Biological Therapy</i> , <b>2012</b> , 12, 1113-24	5.4	123
328	Effects of a restricted sleep regimen on ambulatory blood pressure monitoring in normotensive subjects. <i>American Journal of Hypertension</i> , <b>1996</b> , 9, 503-5	2.3	122
327	Matrix metalloproteinase-2 and -9 levels in obese patients. <i>Endothelium: Journal of Endothelial Cell Research</i> , <b>2008</b> , 15, 219-24		107
326	Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension. <i>Endothelium: Journal of Endothelial Cell Research</i> , <b>2006</b> , 13, 227-31		107
325	Effect of antihypertensive treatment with valsartan or atenolol on sexual activity and plasma testosterone in hypertensive men. <i>European Journal of Clinical Pharmacology</i> , <b>2002</b> , 58, 177-80	2.8	105
324	Effect of curcumin on circulating interleukin-6 concentrations: A systematic review and meta-analysis of randomized controlled trials. <i>Pharmacological Research</i> , <b>2016</b> , 111, 394-404	10.2	102
323	Influence of losartan and atenolol on memory function in very elderly hypertensive patients. <i>Journal of Human Hypertension</i> , <b>2003</b> , 17, 781-5	2.6	101
322	Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in diabetic and healthy subjects. <i>Diabetes and Metabolism</i> , <b>2007</b> , 33, 129-34	5.4	100
321	Exenatide versus glibenclamide in patients with diabetes. <i>Diabetes Technology and Therapeutics</i> , <b>2010</b> , 12, 233-40	8.1	97
320	The role of various peroxisome proliferator-activated receptors and their ligands in clinical practice. <i>Journal of Cellular Physiology</i> , <b>2018</b> , 233, 153-161	7	96
319	Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone. <i>Diabetes, Obesity and Metabolism</i> , <b>2017</b> , 19, 721-728	6.7	95

318	Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. <i>Metabolism: Clinical and Experimental</i> , <b>2010</b> , 59, 887-95	12.7	93
317	The effect of L-carnitine on plasma lipoprotein(a) levels in hypercholesterolemic patients with type 2 diabetes mellitus. <i>Clinical Therapeutics</i> , <b>2003</b> , 25, 1429-39	3.5	92
316	Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. <i>Journal of Human Hypertension</i> , <b>2007</b> , 21, 220-4	2.6	86
315	A role for quercetin in coronavirus disease 2019 (COVID-19). <i>Phytotherapy Research</i> , <b>2021</b> , 35, 1230-1236	6.7	78
314	Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome. <i>Journal of Clinical Pharmacy and Therapeutics</i> , <b>2006</b> , 31, 375-83	2.2	74
313	Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: a 12-month, randomized, double-blind study. <i>Clinical Therapeutics</i> , <b>2004</b> , 26, 1599-607	3.5	74
312	Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive type 2 diabetic patients. <i>American Journal of Hypertension</i> , <b>2002</b> , 15, 1042-9	2.3	72
311	Adipocytokine levels in obese and non-obese subjects: an observational study. <i>Inflammation</i> , <b>2013</b> , 36, 914-20	5.1	71
310	A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome. <i>Diabetes Research and Clinical Practice</i> , <b>2005</b> , 69, 5-13	7.4	70
309	Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alpha. <i>Hypertension Research</i> , <b>2006</b> , 29, 849-56	4.7	70
308	Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial. <i>Clinical Therapeutics</i> , <b>2004</b> , 26, 1599-607	3.5	70
307	Effects of berberine on lipid profile in subjects with low cardiovascular risk. <i>Expert Opinion on Biological Therapy</i> , <b>2013</b> , 13, 475-82	5.4	64
306	Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone. <i>Journal of Clinical Pharmacy and Therapeutics</i> , <b>2007</b> , 32, 261-8	2.2	64
305	Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors. <i>Clinical Therapeutics</i> , <b>2003</b> , 25, 472-84	3.5	64
304	Exosomes: Nanoparticulate tools for RNA interference and drug delivery. <i>Journal of Cellular Physiology</i> , <b>2017</b> , 232, 1660-1668	7	62
303	Effect of valsartan and ramipril on atrial fibrillation recurrence and P-wave dispersion in hypertensive patients with recurrent symptomatic lone atrial fibrillation. <i>American Journal of Hypertension</i> , <b>2008</b> , 21, 1034-9	2.3	62
302	Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both on anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet. <i>Clinical Therapeutics</i> , <b>2003</b> , 25, 1107-22	3.5	60
301	Losartan and perindopril effects on plasma plasminogen activator inhibitor-1 and fibrinogen in hypertensive type 2 diabetic patients. <i>American Journal of Hypertension</i> , <b>2002</b> , 15, 316-20	2.3	60

300	Different effect of psyllium and guar dietary supplementation on blood pressure control in hypertensive overweight patients: a six-month, randomized clinical trial. <i>Clinical and Experimental Hypertension</i> , <b>2007</b> , 29, 383-94	2.2	59
299	Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. <i>European Journal of Pharmacology</i> , <b>2011</b> , 666, 251-6	5.3	57
298	Comparison between metalloproteinases-2 and -9 in healthy subjects, diabetics, and subjects with acute coronary syndrome. <i>Heart and Vessels</i> , <b>2007</b> , 22, 361-70	2.1	55
297	Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial. <i>Clinical Therapeutics</i> , <b>2006</b> , 28, 679-88	3.5	55
296	Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients. <i>Diabetes, Obesity and Metabolism</i> , <b>2005</b> , 7, 47-55	6.7	55
295	Plasma uric acid concentrations are reduced by fenofibrate: A systematic review and meta-analysis of randomized placebo-controlled trials. <i>Pharmacological Research</i> , <b>2015</b> , 102, 63-70	10.2	54
294	Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, $\beta$ cell function and insulin resistance in type 2 diabetic patients. <i>Diabetes Research and Clinical Practice</i> , <b>2012</b> , 98, 51-60	7.4	54
293	Psyllium improves dyslipidaemia, hyperglycaemia and hypertension, while guar gum reduces body weight more rapidly in patients affected by metabolic syndrome following an AHA Step 2 diet. <i>Mediterranean Journal of Nutrition and Metabolism</i> , <b>2010</b> , 3, 47-54	1.3	52
292	Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin. <i>Hypertension Research</i> , <b>2007</b> , 30, 387-94	4.7	52
291	Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: comparison with other oral antihyperglycaemic agents. <i>Drugs</i> , <b>2010</b> , 70, 1945-61	12.1	51
290	Peroxisome proliferator-activated receptor- $\gamma$ (PPAR- $\gamma$ ) agonists on glycemic control, lipid profile and cardiovascular risk. <i>Current Molecular Pharmacology</i> , <b>2012</b> , 5, 272-81	3.7	51
289	Red yeast rice improves lipid pattern, high-sensitivity C-reactive protein, and vascular remodeling parameters in moderately hypercholesterolemic Italian subjects. <i>Nutrition Research</i> , <b>2013</b> , 33, 622-8	4	49
288	Exenatide plus metformin compared with metformin alone on $\beta$ cell function in patients with Type 2 diabetes. <i>Diabetic Medicine</i> , <b>2012</b> , 29, 1515-23	3.5	48
287	Circulating Levels of Proprotein Convertase Subtilisin/Kexin Type 9 and Arterial Stiffness in a Large Population Sample: Data From the Brisighella Heart Study. <i>Journal of the American Heart Association</i> , <b>2017</b> , 6,	6	47
286	Efficacy and safety profile evaluation of acarbose alone and in association with other antidiabetic drugs: a systematic review. <i>Clinical Therapeutics</i> , <b>2012</b> , 34, 1221-36	3.5	47
285	Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin. <i>Diabetes Research and Clinical Practice</i> , <b>2003</b> , 60, 161-9	7.4	47
284	Ellagic Acid and Its Role in Chronic Diseases. <i>Advances in Experimental Medicine and Biology</i> , <b>2016</b> , 928, 473-479	3.6	47
283	What do herbalists suggest to diabetic patients in order to improve glycemic control? Evaluation of scientific evidence and potential risks. <i>Acta Diabetologica</i> , <b>2004</b> , 41, 91-8	3.9	46

282	Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients. <i>Hormone and Metabolic Research</i> , <b>2010</b> , 42, 663-9	3.1	45
281	Dipeptidyl peptidase-4 inhibitors: 3 years of experience. <i>Diabetes Technology and Therapeutics</i> , <b>2012</b> , 14, 350-64	8.1	45
280	Naturally occurring anti-cancer agents targeting EZH2. <i>Cancer Letters</i> , <b>2017</b> , 400, 325-335	9.9	44
279	Potential Clinical Benefits of Quercetin in the Early Stage of COVID-19: Results of a Second, Pilot, Randomized, Controlled and Open-Label Clinical Trial. <i>International Journal of General Medicine</i> , <b>2021</b> , 14, 2807-2816	2.3	44
278	Effects of n-3 PUFAs on postprandial variation of metalloproteinases, and inflammatory and insulin resistance parameters in dyslipidemic patients: evaluation with euglycemic clamp and oral fat load. <i>Journal of Clinical Lipidology</i> , <b>2012</b> , 6, 553-64	4.9	43
277	Comparison of the effects of valsartan and felodipine on plasma leptin and insulin sensitivity in hypertensive obese patients. <i>Hypertension Research</i> , <b>2005</b> , 28, 209-14	4.7	43
276	Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , <b>2016</b> , 374, 1095-6	59.2	42
275	Orlistat and L-carnitine compared to orlistat alone on insulin resistance in obese diabetic patients. <i>Endocrine Journal</i> , <b>2010</b> , 57, 777-86	2.9	42
274	Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride. <i>Hypertension Research</i> , <b>2005</b> , 28, 917-24	4.7	42
273	Dietary and nutraceutical approach to type 2 diabetes. <i>Archives of Medical Science</i> , <b>2014</b> , 10, 336-44	2.9	41
272	Vildagliptin added to metformin on $\beta$ cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients. <i>Diabetes Technology and Therapeutics</i> , <b>2012</b> , 14, 475-84	8.1	41
271	Acarbose actions on insulin resistance and inflammatory parameters during an oral fat load. <i>European Journal of Pharmacology</i> , <b>2011</b> , 651, 240-50	5.3	41
270	Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin. <i>Internal Medicine Journal</i> , <b>2007</b> , 37, 79-86	1.6	40
269	Effects of statin therapy on augmentation index as a measure of arterial stiffness: A systematic review and meta-analysis. <i>International Journal of Cardiology</i> , <b>2016</b> , 212, 160-8	3.2	39
268	Omega 3 polyunsaturated fatty acids supplementation and blood pressure levels in hypertriglyceridemic patients with untreated normal-high blood pressure and with or without metabolic syndrome: a retrospective study. <i>Clinical and Experimental Hypertension</i> , <b>2010</b> , 32, 137-44	2.2	39
267	GLP-1 agonists exenatide and liraglutide: a review about their safety and efficacy. <i>Current Clinical Pharmacology</i> , <b>2012</b> , 7, 214-28	2.5	39
266	A Clinical Trial about a Food Supplement Containing $\alpha$ Lipoic Acid on Oxidative Stress Markers in Type 2 Diabetic Patients. <i>International Journal of Molecular Sciences</i> , <b>2016</b> , 17,	6.3	39
265	Impact of Statin Therapy on Plasma Uric Acid Concentrations: A Systematic Review and Meta-Analysis. <i>Drugs</i> , <b>2016</b> , 76, 947-56	12.1	38

264	Alkaloids in the nature: pharmacological applications in clinical practice of berberine and mate tea. <i>Current Topics in Medicinal Chemistry</i> , <b>2014</b> , 14, 200-6	3	38
263	Possible Therapeutic Effects of Adjuvant Quercetin Supplementation Against Early-Stage COVID-19 Infection: A Prospective, Randomized, Controlled, and Open-Label Study. <i>International Journal of General Medicine</i> , <b>2021</b> , 14, 2359-2366	2.3	38
262	Statin impact on disease activity and C-reactive protein concentrations in systemic lupus erythematosus patients: A systematic review and meta-analysis of controlled trials. <i>Autoimmunity Reviews</i> , <b>2016</b> , 15, 344-53	13.6	37
261	Berberis aristata/Silybum marianum fixed combination on lipid profile and insulin secretion in dyslipidemic patients. <i>Expert Opinion on Biological Therapy</i> , <b>2013</b> , 13, 1495-506	5.4	37
260	Oral fat load effects on inflammation and endothelial stress markers in healthy subjects. <i>Heart and Vessels</i> , <b>2009</b> , 24, 204-10	2.1	37
259	Effect of telmisartan-amlodipine combination at different doses on urinary albumin excretion in hypertensive diabetic patients with microalbuminuria. <i>American Journal of Hypertension</i> , <b>2007</b> , 20, 417-22	2.3	37
258	Piperine and Its Role in Chronic Diseases. <i>Advances in Experimental Medicine and Biology</i> , <b>2016</b> , 928, 173-184	3.4	37
257	Oral glucose tolerance test effects on endothelial inflammation markers in healthy subjects and diabetic patients. <i>Hormone and Metabolic Research</i> , <b>2010</b> , 42, 8-13	3.1	36
256	Effects of pioglitazone and rosiglitazone combined with metformin on body weight in people with diabetes. <i>Diabetes, Obesity and Metabolism</i> , <b>2009</b> , 11, 1091-9	6.7	36
255	Comparative evaluation of effect of valsartan/amlodipine and atenolol/amlodipine combinations on atrial fibrillation recurrence in hypertensive patients with type 2 diabetes mellitus. <i>Journal of Cardiovascular Pharmacology</i> , <b>2008</b> , 51, 217-22	3.1	36
254	Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial. <i>Clinical Therapeutics</i> , <b>2005</b> , 27, 1383-91	3.5	36
253	Effect of amlodipine-atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic patients with insulin resistance. <i>American Journal of Hypertension</i> , <b>2004</b> , 17, 823-7	2.3	36
252	Effects of 1-year orlistat treatment compared to placebo on insulin resistance parameters in patients with type 2 diabetes. <i>Journal of Clinical Pharmacy and Therapeutics</i> , <b>2012</b> , 37, 187-95	2.2	35
251	Effects of amlodipine-atorvastatin combination on inflammation markers and insulin sensitivity in normocholesterolemic obese hypertensive patients. <i>European Journal of Clinical Pharmacology</i> , <b>2006</b> , 62, 817-22	2.8	35
250	Curcumin: A Natural Pan-HDAC Inhibitor in Cancer. <i>Current Pharmaceutical Design</i> , <b>2018</b> , 24, 123-129	3.3	34
249	Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients. <i>Current Medical Research and Opinion</i> , <b>2009</b> , 25, 1973-83	2.5	33
248	Effects of losartan and amlodipine alone or combined with simvastatin in hypertensive patients with nonalcoholic hepatic steatosis. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2012</b> , 24, 164-71	2.2	33
247	Vascular remodeling and prothrombotic markers in subjects affected by familial combined hyperlipidemia and/or metabolic syndrome in primary prevention for cardiovascular disease. <i>Endothelium: Journal of Endothelial Cell Research</i> , <b>2007</b> , 14, 193-8		33

246	Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in combined dyslipidemia. <i>Clinical and Investigative Medicine</i> , <b>2009</b> , 32, E124-32	0.9	32
245	Effects of n-3 pufas on fasting plasma glucose and insulin resistance in patients with impaired fasting glucose or impaired glucose tolerance. <i>BioFactors</i> , <b>2016</b> , 42, 316-22	6.1	32
244	Different actions of losartan and ramipril on adipose tissue activity and vascular remodeling biomarkers in hypertensive patients. <i>Hypertension Research</i> , <b>2011</b> , 34, 145-51	4.7	31
243	Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2006</b> , 8, 197-205	6.7	31
242	Comparative effects of telmisartan and eprosartan on insulin sensitivity in the treatment of overweight hypertensive patients. <i>Hormone and Metabolic Research</i> , <b>2009</b> , 41, 893-8	3.1	30
241	Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial. <i>Current Medical Research and Opinion</i> , <b>2009</b> , 25, 607-15	2.5	30
240	Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin. <i>Journal of Clinical Pharmacy and Therapeutics</i> , <b>2010</b> , 35, 565-79	2.2	29
239	Sibutramine and L-carnitine compared to sibutramine alone on insulin resistance in diabetic patients. <i>Internal Medicine</i> , <b>2010</b> , 49, 1717-25	1.1	29
238	Metalloproteinase-2 and -9 in diabetic and nondiabetic subjects during acute coronary syndromes. <i>Endothelium: Journal of Endothelial Cell Research</i> , <b>2007</b> , 14, 45-51		29
237	Matrix metalloproteinase 2 may be a marker of microangiopathy in children and adolescents with type 1 diabetes mellitus. <i>Diabetes Research and Clinical Practice</i> , <b>2005</b> , 70, 119-25	7.4	29
236	Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients. <i>Diabetes, Nutrition &amp; Metabolism</i> , <b>2004</b> , 17, 222-9		29
235	Effects of combination of sibutramine and L-carnitine compared with sibutramine monotherapy on inflammatory parameters in diabetic patients. <i>Metabolism: Clinical and Experimental</i> , <b>2011</b> , 60, 421-9	12.7	28
234	Effects of thiazolidinediones and sulfonylureas in patients with diabetes. <i>Diabetes Technology and Therapeutics</i> , <b>2010</b> , 12, 491-501	8.1	28
233	Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load. <i>Hormone and Metabolic Research</i> , <b>2011</b> , 43, 505-12	3.1	27
232	A randomized, double-blind, controlled, parallel-group comparison of perindopril and candesartan in hypertensive patients with type 2 diabetes mellitus. <i>Clinical Therapeutics</i> , <b>2003</b> , 25, 2006-21	3.5	27
231	Differential effects of lercanidipine and nifedipine GITS on plasma norepinephrine in chronic treatment of hypertension. <i>American Journal of Hypertension</i> , <b>2003</b> , 16, 596-9	2.3	27
230	Statin therapy and plasma free fatty acids: a systematic review and meta-analysis of controlled clinical trials. <i>British Journal of Clinical Pharmacology</i> , <b>2016</b> , 81, 807-18	3.8	27
229	Efficacy and safety of two treatment combinations of hypertension in very elderly patients. <i>Archives of Gerontology and Geriatrics</i> , <b>2009</b> , 48, 401-5	4	26

228	Effect of delapril-manidipine combination vs irbesartan-hydrochlorothiazide combination on fibrinolytic function in hypertensive patients with type II diabetes mellitus. <i>Journal of Human Hypertension</i> , <b>2004</b> , 18, 687-91	2.6	26
227	Effects of doxazosin and irbesartan on blood pressure and metabolic control in patients with type 2 diabetes and hypertension. <i>Journal of Cardiovascular Pharmacology</i> , <b>2005</b> , 45, 599-604	3.1	26
226	Optimizing combination treatment in the management of type 2 diabetes. <i>Vascular Health and Risk Management</i> , <b>2007</b> , 3, 665-71	4.4	26
225	A systematic review and meta-analysis of randomized controlled trials investigating the effects of supplementation with <i>Nigella sativa</i> (black seed) on blood pressure. <i>Journal of Hypertension</i> , <b>2016</b> , 34, 2127-35	1.9	26
224	Comparison of orlistat treatment and placebo in obese type 2 diabetic patients. <i>Expert Opinion on Pharmacotherapy</i> , <b>2010</b> , 11, 1971-82	4	25
223	Effect of body weight loss and normalization on blood pressure in overweight non-obese patients with stage 1 hypertension. <i>Hypertension Research</i> , <b>2010</b> , 33, 236-42	4.7	25
222	Effect of delapril/manidipine vs olmesartan/ hydrochlorothiazide combination on insulin sensitivity and fibrinogen in obese hypertensive patients. <i>Internal Medicine</i> , <b>2008</b> , 47, 361-6	1.1	25
221	<i>Berberis aristata</i> combined with <i>Silybum marianum</i> on lipid profile in patients not tolerating statins at high doses. <i>Atherosclerosis</i> , <b>2015</b> , 239, 87-92	3.1	24
220	Effects of a standardized oral fat load on vascular remodelling markers in healthy subjects. <i>Microvascular Research</i> , <b>2010</b> , 80, 110-5	3.7	24
219	Long-term effect of glimepiride and rosiglitazone on non-conventional cardiovascular risk factors in metformin-treated patients affected by metabolic syndrome: a randomized, double-blind clinical trial. <i>Journal of International Medical Research</i> , <b>2005</b> , 33, 284-94	1.4	24
218	Effects of metformin extended release compared to immediate release formula on glycemic control and glycemic variability in patients with type 2 diabetes. <i>Drug Design, Development and Therapy</i> , <b>2017</b> , 11, 1481-1488	4.4	23
217	Prevalence and associations of erectile dysfunction in a sample of Italian males with type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , <b>2015</b> , 108, 329-35	7.4	23
216	Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients. <i>Metabolism: Clinical and Experimental</i> , <b>2014</b> , 63, 957-67	12.7	23
215	Sitagliptin added to previously taken antidiabetic agents on insulin resistance and lipid profile: a 2-year study evaluation. <i>Fundamental and Clinical Pharmacology</i> , <b>2014</b> , 28, 221-9	3.1	23
214	Effect of telmisartan on paroxysmal atrial fibrillation recurrence in hypertensive patients with normal or increased left atrial size. <i>Clinical Cardiology</i> , <b>2012</b> , 35, 359-64	3.3	23
213	Variations in inflammatory biomarkers following the addition of sitagliptin in patients with type 2 diabetes not controlled with metformin. <i>Internal Medicine</i> , <b>2013</b> , 52, 2179-87	1.1	23
212	Different effects of aliskiren and losartan on fibrinolysis and insulin sensitivity in hypertensive patients with metabolic syndrome. <i>Hormone and Metabolic Research</i> , <b>2010</b> , 42, 892-6	3.1	23
211	Comparison between orlistat plus l-carnitine and orlistat alone on inflammation parameters in obese diabetic patients. <i>Fundamental and Clinical Pharmacology</i> , <b>2011</b> , 25, 642-51	3.1	22



210	Modification of vascular and inflammation biomarkers after OGTT in overweight healthy and diabetic subjects. <i>Microvascular Research</i> , <b>2010</b> , 79, 144-9	3.7	22
209	Effects of long chain omega-3 fatty acids on metalloproteinases and their inhibitors in combined dyslipidemia patients. <i>Expert Opinion on Pharmacotherapy</i> , <b>2009</b> , 10, 1239-47	4	22
208	Effects of Siberian ginseng ( <i>Eleutherococcus senticosus maxim.</i> ) on elderly quality of life: a randomized clinical trial. <i>Archives of Gerontology and Geriatrics</i> , <b>2004</b> , 38, 69-73	4	22
207	Adipose tissue dysfunction and metabolic disorders: Is it possible to predict who will develop type 2 diabetes mellitus? Role of markers in the progression of diabetes in obese patients (The RESISTIN trial). <i>Cytokine</i> , <b>2020</b> , 127, 154947	4	22
206	Effect of telmisartan and ramipril on atrial fibrillation recurrence and severity in hypertensive patients with metabolic syndrome and recurrent symptomatic paroxysmal and persistent atrial fibrillation. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , <b>2012</b> , 17, 34-43	2.6	21
205	Role of angiotensin II in plasma PAI-1 changes induced by imidapril or candesartan in hypertensive patients with metabolic syndrome. <i>Hypertension Research</i> , <b>2011</b> , 34, 1321-6	4.7	21
204	Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , <b>2011</b> , 4, 263-71	3.4	21
203	Differential effects of candesartan and olmesartan on adipose tissue activity biomarkers in type II diabetic hypertensive patients. <i>Hypertension Research</i> , <b>2010</b> , 33, 790-5	4.7	21
202	Vildagliptin action on some adipocytokine levels in type 2 diabetic patients: a 12-month, placebo-controlled study. <i>Expert Opinion on Pharmacotherapy</i> , <b>2012</b> , 13, 2581-91	4	21
201	Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: comparison between glimepiride and metformin. <i>Diabetes, Nutrition &amp; Metabolism</i> , <b>2004</b> , 17, 143-50		21
200	Effects of nateglinide and glibenclamide on prothrombotic factors in naïve type 2 diabetic patients treated with metformin: a 1-year, double-blind, randomized clinical trial. <i>Internal Medicine</i> , <b>2007</b> , 46, 1837-46	4.1	20
199	Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial. <i>Clinical Therapeutics</i> , <b>2007</b> , 29, 602-10	3.5	20
198	Improvement of plasma adiponectin, leptin and C-reactive protein concentrations by orlistat: a systematic review and meta-analysis. <i>British Journal of Clinical Pharmacology</i> , <b>2016</b> , 81, 819-34	3.8	20
197	The role of a fixed <i>Berberis aristata</i> / <i>Silybum marianum</i> combination in the treatment of type 1 diabetes mellitus. <i>Clinical Nutrition</i> , <b>2016</b> , 35, 1091-5	5.9	19
196	Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone: a randomized placebo-controlled trial. <i>Pharmacotherapy</i> , <b>2013</b> , 33, 817-26	5.8	19
195	Thiazolidinediones plus metformin association on body weight in patients with type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , <b>2011</b> , 91, 265-70	7.4	19
194	<i>Berberis aristata</i> / <i>Silybum marianum</i> fixed combination (Berberol(®)) effects on lipid profile in dyslipidemic patients intolerant to statins at high dosages: a randomized, placebo-controlled, clinical trial. <i>Phytomedicine</i> , <b>2015</b> , 22, 231-7	6.5	18
193	A randomized, double-blind, placebo-controlled trial evaluating sitagliptin action on insulin resistance parameters and βcell function. <i>Expert Opinion on Pharmacotherapy</i> , <b>2012</b> , 13, 2433-42	4	18

192	Candesartan effect on inflammation in hypertension. <i>Hypertension Research</i> , <b>2010</b> , 33, 209-13	4.7	18
191	Evaluation of emerging biomarkers in cardiovascular risk stratification of hypertensive patients: a 2-year study. <i>Current Medical Research and Opinion</i> , <b>2012</b> , 28, 1435-45	2.5	18
190	Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60G study. <i>Metabolism: Clinical and Experimental</i> , <b>2009</b> , 58, 1059-66	12.7	18
189	Effects of manidipine/delapril versus olmesartan/hydrochlorothiazide combination therapy in elderly hypertensive patients with type 2 diabetes mellitus. <i>Hypertension Research</i> , <b>2008</b> , 31, 43-50	4.7	18
188	Effects of rosiglitazone and pioglitazone combined with metformin on the prothrombotic state of patients with type 2 diabetes mellitus and metabolic syndrome. <i>Journal of International Medical Research</i> , <b>2006</b> , 34, 545-55	1.4	18
187	Awareness of major cardiovascular risk factors and its relationship with markers of vascular aging: Data from the Brisighella Heart Study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , <b>2020</b> , 30, 907-914	4.5	17
186	Effect of a food supplement containing berberine, monacolin K, hydroxytyrosol and coenzyme Q on lipid levels: a randomized, double-blind, placebo controlled study. <i>Drug Design, Development and Therapy</i> , <b>2017</b> , 11, 1585-1592	4.4	17
185	Drug safety evaluation of amlodipine. <i>Expert Opinion on Drug Safety</i> , <b>2011</b> , 10, 795-804	4.1	17
184	Efficacy and safety of ezetimibe/simvastatin association on non-diabetic and diabetic patients with polygenic hypercholesterolemia or combined hyperlipidemia and previously intolerant to standard statin treatment. <i>Journal of Clinical Pharmacy and Therapeutics</i> , <b>2009</b> , 34, 267-76	2.2	17
183	Combined lipoxygenase/cyclo-oxygenase inhibition in the elderly: the example of licofelone. <i>Drugs and Aging</i> , <b>2005</b> , 22, 393-403	4.7	17
182	Matrix metalloproteinase 2 may be a marker of microangiopathy in children and adolescents with type 1 diabetes. <i>Diabetes Care</i> , <b>2004</b> , 27, 273-4	14.6	17
181	Treatment of massive hypertriglyceridemia resistant to PUFA and fibrates: a possible role for the coenzyme Q10?. <i>BioFactors</i> , <b>2005</b> , 23, 7-14	6.1	17
180	A review about biomarkers for the investigation of vascular function and impairment in diabetes mellitus. <i>Vascular Health and Risk Management</i> , <b>2016</b> , 12, 415-419	4.4	17
179	Effects of n-3 PUFA on insulin resistance after an oral fat load. <i>European Journal of Lipid Science and Technology</i> , <b>2011</b> , 113, 950-960	3	16
178	Continuous glucose monitoring system in free-living healthy subjects: results from a pilot study. <i>Diabetes Technology and Therapeutics</i> , <b>2009</b> , 11, 159-69	8.1	16
177	Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome. <i>Pharmacotherapy</i> , <b>2005</b> , 25, 637-45	5.8	16
176	Curcuminoids Lower Plasma Leptin Concentrations: A Meta-analysis. <i>Phytotherapy Research</i> , <b>2017</b> , 31, 1836-1841	6.7	15
175	Rosiglitazone therapy improves insulin resistance parameters in overweight and obese diabetic patients intolerant to metformin. <i>Archives of Medical Research</i> , <b>2008</b> , 39, 412-9	6.6	15

174	Effect of valsartan addition to amlodipine on insulin sensitivity in overweight-obese hypertensive patients. <i>Internal Medicine</i> , <b>2008</b> , 47, 1851-7	1.1	15
173	Hydrochlorothiazide added to valsartan is more effective than when added to olmesartan in reducing blood pressure in moderately hypertensive patients inadequately controlled by monotherapy. <i>Advances in Therapy</i> , <b>2006</b> , 23, 680-95	4.1	15
172	Two-year statin therapy does not alter the progression of intima-media thickness in patients with type 2 diabetes without manifest cardio-vascular disease: response to Beishuizen et al. <i>Diabetes Care</i> , <b>2005</b> , 28, 1262-3; author reply 1263-4	14.6	15
171	Effects of orlistat, simvastatin, and orlistat + simvastatin in obese patients with hypercholesterolemia: a randomized, open-label trial. <i>Current Therapeutic Research</i> , <b>2002</b> , 63, 621-633	2.4	15
170	Auraptene and Its Role in Chronic Diseases. <i>Advances in Experimental Medicine and Biology</i> , <b>2016</b> , 929, 399-407	3.6	14
169	Long-term predictors of impaired fasting glucose and type 2 diabetes in subjects with family history of type 2 diabetes: a 12-years follow-up of the Brisighella Heart Study historical cohort. <i>Diabetes Research and Clinical Practice</i> , <b>2014</b> , 104, 183-8	7.4	14
168	Losartan and amlodipine on myocardial structure and function: a prospective, randomized, clinical trial. <i>Diabetic Medicine</i> , <b>2012</b> , 29, 24-31	3.5	14
167	A randomized, double-blind, comparative therapy evaluating sitagliptin versus glibenclamide in type 2 diabetes patients already treated with pioglitazone and metformin: a 3-year study. <i>Diabetes Technology and Therapeutics</i> , <b>2013</b> , 15, 214-22	8.1	14
166	Effects of exenatide and metformin in combination on some adipocytokine levels: a comparison with metformin monotherapy. <i>Canadian Journal of Physiology and Pharmacology</i> , <b>2013</b> , 91, 724-32	2.4	14
165	Nateglinide and glibenclamide metabolic effects in naïve type 2 diabetic patients treated with metformin. <i>Journal of Clinical Pharmacy and Therapeutics</i> , <b>2009</b> , 34, 13-23	2.2	14
164	Modulation of adipokines and vascular remodelling markers during OGTT with acarbose or pioglitazone treatment. <i>Biomedicine and Pharmacotherapy</i> , <b>2009</b> , 63, 723-33	7.5	14
163	Red yeast rice and statin-intolerant patients. <i>American Journal of Cardiology</i> , <b>2010</b> , 105, 1504	3	14
162	Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone. <i>Metabolism: Clinical and Experimental</i> , <b>2008</b> , 57, 1552-7	12.7	14
161	Pioglitazone and rosiglitazone: effects of treatment with a thiazolidinedione on lipids and non conventional cardiovascular risk factors. <i>Current Clinical Pharmacology</i> , <b>2008</b> , 3, 77-84	2.5	14
160	Possible role of ubiquinone in the treatment of massive hypertriglyceridemia resistant to PUFA and fibrates. <i>Biomedicine and Pharmacotherapy</i> , <b>2005</b> , 59, 312-7	7.5	14
159	Effects of Berberis aristata/Silybum marianum association on metabolic parameters and adipocytokines in overweight dyslipidemic patients. <i>Journal of Biological Regulators and Homeostatic Agents</i> , <b>2013</b> , 27, 717-28	0.7	14
158	Sitagliptin in type 2 diabetes mellitus: Efficacy after five years of therapy. <i>Pharmacological Research</i> , <b>2015</b> , 100, 127-34	10.2	13
157	Testing the Short-Term Efficacy of a Lipid-Lowering Nutraceutical in the Setting of Clinical Practice: A Multicenter Study. <i>Journal of Medicinal Food</i> , <b>2015</b> , 18, 1270-3	2.8	13

156	Barnidipine compared to lercanidipine in addition to losartan on endothelial damage and oxidative stress parameters in patients with hypertension and type 2 diabetes mellitus. <i>BMC Cardiovascular Disorders</i> , <b>2016</b> , 16, 66	2.3	13
155	Fibrinolysis and insulin sensitivity in imidapril and candesartan (FISIC study) recipients with hypertension. <i>Hypertension Research</i> , <b>2011</b> , 34, 509-15	4.7	13
154	Effectiveness of hydrochlorothiazide in combination with telmisartan and olmesartan in adults with moderate hypertension not controlled with monotherapy: a prospective, randomized, open-label, blinded end point (PROBE), parallel-arm study. <i>Current Therapeutic Research</i> , <b>2008</b> , 69, 1-15	2.4	13
153	Smaller, denser LDL particles are not a risk factor for cardiovascular disease in healthy nonagenarian women of the Cremona Population Study. <i>Atherosclerosis</i> , <b>1998</b> , 140, 65-70	3.1	13
152	Relationship between serum uric acid and electrocardiographic alterations in a large sample of general population: data from the Brisighella Heart Study. <i>High Blood Pressure and Cardiovascular Prevention</i> , <b>2015</b> , 22, 129-34	2.9	12
151	Effects on oral fat load of a nutraceutical combination of fermented red rice, sterol esters and stanols, curcumin, and olive polyphenols: A randomized, placebo controlled trial. <i>Phytomedicine</i> , <b>2018</b> , 42, 75-82	6.5	12
150	Comparison of vildagliptin and glimepiride: effects on glycaemic control, fat tolerance and inflammatory markers in people with type 2 diabetes. <i>Diabetic Medicine</i> , <b>2014</b> , 31, 1515-23	3.5	12
149	Comparison of the effects of barnidipine+losartan compared with telmisartan+hydrochlorothiazide on several parameters of insulin sensitivity in patients with hypertension and type 2 diabetes mellitus. <i>Hypertension Research</i> , <b>2015</b> , 38, 690-4	4.7	12
148	Effects of canrenone in patients with metabolic syndrome. <i>Expert Opinion on Pharmacotherapy</i> , <b>2013</b> , 14, 2161-9	4	12
147	Effects of a Combination of Berberis aristata, Silybum marianum and Monacolin on Lipid Profile in Subjects at Low Cardiovascular Risk; A Double-Blind, Randomized, Placebo-Controlled Trial. <i>International Journal of Molecular Sciences</i> , <b>2017</b> , 18,	6.3	12
146	Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2013</b> , 25, 1113-22	2.2	12
145	Effects of amlodipine plus atorvastatin association in hypertensive hypercholesterolemic patients. <i>Expert Review of Cardiovascular Therapy</i> , <b>2010</b> , 8, 835-43	2.5	12
144	Effect of telmisartan addition to amlodipine on ankle edema development in treating hypertensive patients. <i>Expert Opinion on Pharmacotherapy</i> , <b>2011</b> , 12, 2441-8	4	12
143	Effect of aliskiren addition to amlodipine on ankle edema in hypertensive patients: a three-way crossover study. <i>Expert Opinion on Pharmacotherapy</i> , <b>2011</b> , 12, 1351-8	4	12
142	IFN-gamma low production capacity in type 1 diabetes mellitus patients at onset of disease. <i>Experimental and Clinical Endocrinology and Diabetes</i> , <b>2005</b> , 113, 313-7	2.3	12
141	Change of some oxidative stress parameters after supplementation with whey protein isolate in patients with type 2 diabetes. <i>Nutrition</i> , <b>2020</b> , 73, 110700	4.8	12
140	Effect of ezetimibe on plasma adipokines: a systematic review and meta-analysis. <i>British Journal of Clinical Pharmacology</i> , <b>2017</b> , 83, 1380-1396	3.8	11
139	Effects of aliskiren on QT duration and dispersion in hypertensive patients with type 2 diabetes mellitus. <i>Diabetes, Obesity and Metabolism</i> , <b>2012</b> , 14, 341-7	6.7	11

138	Effect of naproxen and acetaminophen on blood pressure lowering by ramipril, valsartan and aliskiren in hypertensive patients. <i>Expert Opinion on Pharmacotherapy</i> , <b>2013</b> , 14, 1875-84	4	11
137	Comparative effect of canrenone or hydrochlorothiazide addition to valsartan/amlodipine combination on urinary albumin excretion in well-controlled type 2 diabetic hypertensive patients with microalbuminuria. <i>Expert Opinion on Pharmacotherapy</i> , <b>2014</b> , 15, 453-9	4	11
136	Effect of valsartan or olmesartan addition to amlodipine on ankle edema in hypertensive patients. <i>Advances in Therapy</i> , <b>2010</b> , 27, 48-55	4.1	11
135	Metalloproteinases in diabetics and nondiabetics during acute coronary syndromes and after 3 months. <i>Endothelium: Journal of Endothelial Cell Research</i> , <b>2007</b> , 14, 175-83		11
134	Efficacy and tolerability of candesartan cilexetil/hydrochlorothiazide and amlodipine in patients with poorly controlled mild-to-moderate essential hypertension. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , <b>2007</b> , 8, 139-44	3	11
133	Quercetin Phytosome as a potential candidate for managing COVID-19. <i>Minerva Gastroenterology</i> , <b>2021</b> , 67, 190-195	3	11
132	A randomized, placebo-controlled study on the effects of a nutraceutical combination of red yeast rice, silybum marianum and octasonol on lipid profile, endothelial and inflammatory parameters. <i>Journal of Biological Regulators and Homeostatic Agents</i> , <b>2014</b> , 28, 317-24	0.7	11
131	A comparison between sitagliptin or glibenclamide in addition to metformin + pioglitazone on glycaemic control and $\beta$ cell function: the triple oral therapy. <i>Diabetic Medicine</i> , <b>2013</b> , 30, 846-54	3.5	10
130	Effects of one year treatment of sibutramine on insulin resistance parameters in type 2 diabetic patients. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , <b>2010</b> , 13, 378-90	3.4	10
129	Pioglitazone is a valid alternative to rosiglitazone. <i>American Journal of Cardiovascular Drugs</i> , <b>2011</b> , 11, 357-62	4	10
128	Effect of a sequential training programme on inflammatory, prothrombotic and vascular remodelling biomarkers in hypertensive overweight patients with or without metabolic syndrome. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , <b>2009</b> , 16, 698-704		10
127	Pioglitazone metabolic effect in metformin-intolerant obese patients treated with sibutramine. <i>Internal Medicine</i> , <b>2009</b> , 48, 265-71	1.1	10
126	Efficacy of losartan, valsartan, and telmisartan in patients with mild to moderate hypertension: A double-blind, placebo-controlled, crossover study using ambulatory blood pressure monitoring. <i>Current Therapeutic Research</i> , <b>2002</b> , 63, 1-14	2.4	10
125	Ascophyllum nodosum and Fucus vesiculosus on glycaemic status and on endothelial damage markers in dysglycaemic patients. <i>Phytotherapy Research</i> , <b>2019</b> , 33, 791-797	6.7	9
124	Perindopril and barnidipine alone or combined with simvastatin on hepatic steatosis and inflammatory parameters in hypertensive patients. <i>European Journal of Pharmacology</i> , <b>2015</b> , 766, 31-6	5.3	9
123	An Evaluation of a Nutraceutical with Berberine, Curcumin, Inositol, Banaba and Chromium Picolinate in Patients with Fasting Dysglycemia. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , <b>2020</b> , 13, 653-661	3.4	9
122	Coenzyme q10 liquid supplementation in dyslipidemic subjects with statin-related clinical symptoms: a double-blind, randomized, placebo-controlled study. <i>Drug Design, Development and Therapy</i> , <b>2019</b> , 13, 3647-3655	4.4	9
121	Effects of enalapril/lercanidipine combination on some emerging biomarkers in cardiovascular risk stratification in hypertensive patients. <i>Journal of Clinical Pharmacy and Therapeutics</i> , <b>2014</b> , 39, 277-85	2.2	9

120	Factors associated with 2-year persistence in fully non reimbursed lipid-lowering treatments. <i>Atherosclerosis</i> , <b>2014</b> , 235, 81-3	3.1	9
119	Glyco-metabolic profile among type 2 diabetic patients with erectile dysfunction. <i>Endocrine Journal</i> , <b>2012</b> , 59, 611-9	2.9	9
118	Effects of valsartan or ramipril addition to amlodipine/hydrochlorothiazide combination on left ventricular mass in diabetic hypertensive patients with left ventricular hypertrophy. <i>Expert Opinion on Pharmacotherapy</i> , <b>2012</b> , 13, 1091-9	4	9
117	Synergistic effect of doxazosin and acarbose in improving metabolic control in patients with impaired glucose tolerance. <i>Clinical Drug Investigation</i> , <b>2006</b> , 26, 529-39	3.2	9
116	Effect of pistachio on brachial artery diameter and flow-mediated dilatation: A systematic review and meta-analysis of randomized, controlled-feeding clinical studies. <i>Critical Reviews in Food Science and Nutrition</i> , <b>2019</b> , 59, 328-335	11.5	9
115	High-dose atorvastatin versus moderate dose on early vascular protection after ST-elevation myocardial infarction. <i>Drug Design, Development and Therapy</i> , <b>2017</b> , 11, 3425-3434	4.4	8
114	Variation of inflammatory parameters after sibutramine treatment compared to placebo in type 2 diabetic patients. <i>Journal of Clinical Pharmacy and Therapeutics</i> , <b>2011</b> , 36, 592-601	2.2	8
113	Valsartan addition to amlodipine is more effective than losartan addition in hypertensive patients inadequately controlled by amlodipine. <i>Vascular Health and Risk Management</i> , <b>2010</b> , 6, 87-93	4.4	8
112	Effects of valsartan versus olmesartan addition to amlodipine/hydrochlorothiazide combination in treating stage 2 hypertensive patients. <i>Expert Opinion on Pharmacotherapy</i> , <b>2012</b> , 13, 629-36	4	8
111	Gender-specific haemodynamic and metabolic effects of a sequential training programme on overweight-obese hypertensives. <i>Blood Pressure</i> , <b>2009</b> , 18, 111-6	1.7	8
110	Nutraceuticals for the treatment of metabolic diseases: evidence from clinical practice. <i>Expert Review of Endocrinology and Metabolism</i> , <b>2015</b> , 10, 297-304	4.1	7
109	Results from a 12 months, randomized, clinical trial comparing an olmesartan/amlodipine single pill combination to olmesartan and amlodipine monotherapies on blood pressure and inflammation. <i>European Journal of Pharmaceutical Sciences</i> , <b>2014</b> , 51, 26-33	5.1	7
108	Variation of some inflammatory markers in hypertensive patients after 1 year of olmesartan/amlodipine single-pill combination compared with olmesartan or amlodipine monotherapies. <i>Journal of the American Society of Hypertension</i> , <b>2013</b> , 7, 32-9		7
107	A study about the relevance of adding acetylsalicylic acid in primary prevention in subjects with type 2 diabetes mellitus: effects on some new emerging biomarkers of cardiovascular risk. <i>Cardiovascular Diabetology</i> , <b>2015</b> , 14, 95	8.7	7
106	The effects of canrenone on inflammatory markers in patients with metabolic syndrome. <i>Annals of Medicine</i> , <b>2015</b> , 47, 47-52	1.5	7
105	Time to achieve blood pressure goal with a combination versus a conventional monotherapy approach in hypertensive patients with metabolic syndrome. <i>Clinical and Experimental Hypertension</i> , <b>2010</b> , 32, 245-50	2.2	7
104	Effect of doxazosin on C-reactive protein plasma levels and on nitric oxide in patients with hypertension. <i>Journal of Cardiovascular Pharmacology</i> , <b>2006</b> , 47, 508-12	3.1	7
103	Effect of Sibutramine on Plasma C-Reactive Protein, Leptin and Adiponectin Concentrations: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Current Pharmaceutical Design</i> , <b>2017</b> , 23, 870-878	3.3	7

102	Lipid-lowering nutraceuticals update on scientific evidence. <i>Journal of Cardiovascular Medicine</i> , <b>2020</b> , 21, 845-859	1.9	7
101	Retargeting the management of hypercholesterolemia - focus on evolocumab. <i>Therapeutics and Clinical Risk Management</i> , <b>2016</b> , 12, 1365-76	2.9	7
100	Ertugliflozin: a sodium-glucose cotransporter-2 (SGLT-2) inhibitor for glycemic control in type 2 diabetes. <i>Therapeutics and Clinical Risk Management</i> , <b>2018</b> , 14, 1637-1640	2.9	7
99	Effects of two different dialytic treatments on inflammatory markers in people with end-stage renal disease with and without type 2 diabetes mellitus. <i>Cytokine</i> , <b>2017</b> , 92, 75-79	4	6
98	Glucose-lowering effect and glycaemic variability of insulin glargine, insulin detemir and insulin lispro protamine in people with type 1 diabetes. <i>Diabetes, Obesity and Metabolism</i> , <b>2015</b> , 17, 554-559	6.7	6
97	Olmesartan Combined With Amlodipine on Oxidative Stress Parameters in Type 2 Diabetics, Compared With Single Therapies: A Randomized, Controlled, Clinical Trial. <i>Medicine (United States)</i> , <b>2016</b> , 95, e3084	1.8	6
96	Influence of metabolic syndrome superposition on familial combined hyperlipoproteinemia cardiovascular complication rate. <i>Archives of Medical Science</i> , <b>2013</b> , 9, 238-42	2.9	6
95	Pioglitazone plus glimepiride: a promising alternative in metabolic control. <i>International Journal of Clinical Practice</i> , <b>2007</b> , 61, 28-36	2.9	6
94	Prospects for the development of novel anti-hyperlipidemic drugs. <i>Current Opinion in Investigational Drugs</i> , <b>2006</b> , 7, 826-33		6
93	Effects of Sitagliptin on Lipid Profile in Patients With Type 2 Diabetes Mellitus After 7 Years of Therapy. <i>Journal of Clinical Pharmacology</i> , <b>2019</b> , 59, 1391-1399	2.9	5
92	Ascophyllum Nodosum, Fucus Vesiculosus and chromium picolinate nutraceutical composition can help to treat type 2 diabetic patients. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , <b>2019</b> , 12, 1861-1865	3.4	5
91	Different aspects of sartan + calcium antagonist association compared to the single therapy on inflammation and metabolic parameters in hypertensive patients. <i>Inflammation</i> , <b>2014</b> , 37, 154-62	5.1	5
90	Enalapril/lercanidipine combination on markers of cardiovascular risk: a randomized study. <i>Journal of the American Society of Hypertension</i> , <b>2014</b> , 8, 422-8		5
89	Olmesartan/amlodipine combination versus olmesartan or amlodipine monotherapies on blood pressure and insulin resistance in a sample of hypertensive patients. <i>Clinical and Experimental Hypertension</i> , <b>2013</b> , 35, 301-7	2.2	5
88	Efficacy and safety of two dosages of canrenone as add-on therapy in hypertensive patients taking ace-inhibitors or angiotensin II receptor blockers and hydrochlorothiazide at maximum dosage in a randomized clinical trial: The ESCAPE-IT trial. <i>Cardiovascular Therapeutics</i> , <b>2017</b> , 35, 47-54	3.3	5
87	Effect of Acarbose on Glycemic Variability in Patients with Poorly Controlled Type 2 Diabetes Mellitus Receiving Stable Background Therapy: A Placebo-Controlled Trial. <i>Pharmacotherapy</i> , <b>2015</b> , 35, 983-90	5.8	5
86	Effects of insulin therapy with continuous subcutaneous insulin infusion (CSII) in diabetic patients: comparison with multi-daily insulin injections therapy (MDI). <i>Endocrine Journal</i> , <b>2009</b> , 56, 571-8	2.9	5
85	Psoriasis and Diabetes, a Dangerous Association: Evaluation of Insulin Resistance, Lipid Abnormalities, and Cardiovascular Risk Biomarkers. <i>Frontiers in Medicine</i> , <b>2021</b> , 8, 605691	4.9	5

84	Quercetin Phytosome□ as a potential candidate for managing COVID-19. <i>Minerva Gastroenterology</i> , <b>2021</b> , 67,	3	5
83	Metformin powder formulation compared to metformin tablets on glycemic control and on treatment satisfaction in subjects with type 2 diabetes mellitus. <i>Journal of Clinical Pharmacology</i> , <b>2015</b> , 55, 409-14	2.9	4
82	Safety and Efficacy of Alpha Lipoic Acid During 4 Years of Observation: A Retrospective, Clinical Trial in Healthy Subjects in Primary Prevention. <i>Drug Design, Development and Therapy</i> , <b>2020</b> , 14, 5367-5374	4.4	4
81	Ambulatory blood pressure parameters after canrenone addition to existing treatment regimens with maximum tolerated dose of angiotensin-converting enzyme inhibitors/angiotensin II type 1 receptor blockers plus hydrochlorothiazide in uncontrolled hypertensive patients. <i>Drug Design, Development and Therapy</i> , <b>2017</b> , 11, 3333-3340	4.4	4
80	Effects of an olmesartan/amlodipine fixed dose on blood pressure control, some adipocytokines and interleukins levels compared with olmesartan or amlodipine monotherapies. <i>Journal of Clinical Pharmacy and Therapeutics</i> , <b>2013</b> , 38, 48-55	2.2	4
79	Evaluation of the Effects of Mesoglycan on Some Markers of Endothelial Damage and Walking Distance in Diabetic Patients with Peripheral Arterial Disease. <i>International Journal of Molecular Sciences</i> , <b>2017</b> , 18,	6.3	4
78	Are there mild and serious metabolic syndromes? The need for a graded diagnosis. <i>Journal of Cardiovascular Medicine</i> , <b>2014</b> , 15, 759-60	1.9	4
77	Assessment and management of left ventricular hypertrophy in Type 2 diabetes patients with high blood pressure. <i>Expert Review of Cardiovascular Therapy</i> , <b>2013</b> , 11, 719-28	2.5	4
76	Evaluation of safety and efficacy of a fixed olmesartan/amlodipine combination therapy compared to single monotherapies. <i>Expert Opinion on Drug Safety</i> , <b>2013</b> , 12, 621-9	4.1	4
75	Time course of antiproteinuric effect of aliskiren in arterial hypertension associated with type 2 diabetes and microalbuminuria. <i>Expert Opinion on Pharmacotherapy</i> , <b>2013</b> , 14, 371-84	4	4
74	Endothelial function, blood pressure control, and risk modification: impact of irbesartan alone or in combination. <i>Integrated Blood Pressure Control</i> , <b>2010</b> , 3, 21-30	3.5	4
73	Recommendations for the treatment of hypertension in patients with DM: critical evaluation based on clinical trials. <i>Current Clinical Pharmacology</i> , <b>2006</b> , 1, 21-33	2.5	4
72	Perindopril and candesartan comparative efficacy and safety in type II diabetic hypertensive patients. <i>Journal of Human Hypertension</i> , <b>2003</b> , 17, 433-5	2.6	4
71	Efficacy and Safety of Ertugliflozin in Patients with Type□2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea: A Sub-Study of VERTIS CV. <i>Diabetes Therapy</i> , <b>2021</b> , 12, 1279-1297	3.6	4
70	A randomized, double-blind clinical trial of canrenone vs hydrochlorothiazide in addition to angiotensin II receptor blockers in hypertensive type 2 diabetic patients. <i>Drug Design, Development and Therapy</i> , <b>2018</b> , 12, 2611-2616	4.4	4
69	Evaluation of BAG3 levels in healthy subjects, hypertensive patients, and hypertensive diabetic patients. <i>Journal of Cellular Physiology</i> , <b>2018</b> , 233, 1791-1795	7	3
68	Effect of imidapril versus ramipril on urinary albumin excretion in hypertensive patients with type 2 diabetes and microalbuminuria. <i>Expert Opinion on Pharmacotherapy</i> , <b>2013</b> , 14, 2463-73	4	3
67	Barnidipine or Lercanidipine on Echocardiographic Parameters in Hypertensive, Type 2 Diabetics with Left Ventricular Hypertrophy: A Randomized Clinical Trial. <i>Scientific Reports</i> , <b>2015</b> , 5, 12603	4.9	3



66	A nutraceutical based approach to reduce cholesterolaemia in patients previously intolerant of more than a statin: a pilot study. <i>Mediterranean Journal of Nutrition and Metabolism</i> , <b>2008</b> , 1, 33-36	1.3	3
65	Effect of oral chronic isoflavones supplementation on male rat sexual performances and sexual hormone plasma levels. <i>Phytotherapy Research</i> , <b>2004</b> , 18, 849-52	6.7	3
64	Effects of fosinopril on blood pressure, lipid profile, and lipoprotein(a) levels in normotensive patients with type 2 diabetes and microalbuminuria: An open-label, uncontrolled study. <i>Current Therapeutic Research</i> , <b>2002</b> , 63, 216-226	2.4	3
63	Pioglitazone and metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapy. <i>Core Evidence</i> , <b>2008</b> , 2, 189-98	4.9	3
62	Glyco-metabolic control, inflammation markers, and cardiovascular outcomes in type 1 and type 2 diabetic patients on insulin pump or multiple daily injection (italico study). <i>Diabetes/Metabolism Research and Reviews</i> , <b>2020</b> , 36, e3219	7.5	3
61	EXAMINE: targeting risk and treatment in diabetes. <i>Lancet, The</i> , <b>2015</b> , 386, 1443	4.0	2
60	LONG-TERM EFFECTS OF A BERBERINE BASED NUTRACEUTICAL ON BODY WEIGHT AND INSULIN-SENSITIVITY IN NON DIABETIC HYPERLIPIDAEMIC PATIENTS. <i>Journal of Hypertension</i> , <b>2011</b> , 29, e160	1.9	2
59	Nateglinide does not reduce the incidence of diabetes or cardiovascular outcomes in people with impaired glucose tolerance and cardiovascular disease or risk factors. <i>Evidence-Based Medicine</i> , <b>2011</b> , 16, 7-8		2
58	Nifedipine and telmisartan for the treatment of hypertension: the TALENT study. <i>Expert Review of Cardiovascular Therapy</i> , <b>2011</b> , 9, 1499-503	2.5	2
57	Irbesartan and hydrochlorothiazide association in the treatment of hypertension. <i>Current Vascular Pharmacology</i> , <b>2009</b> , 7, 120-36	3.3	2
56	A nutraceutical based approach to reduce cholesterolaemia in patients previously intolerant of more than a statin: a pilot study. <i>Mediterranean Journal of Nutrition and Metabolism</i> , <b>2008</b> , 1, 33-36	1.3	2
55	Matrix Metalloproteinase-2, -9 and Tissue Inhibitor Metalloproteinase-1 in Patients with Hypertension Before and After Doxazosin Therapy. <i>High Blood Pressure and Cardiovascular Prevention</i> , <b>2006</b> , 13, 47-52	2.9	2
54	PCSK-9 Inhibitors in a Real-World Setting and a Comparison Between Alirocumab and Evolocumab in Heterozygous FH Patients. <i>Journal of the Endocrine Society</i> , <b>2021</b> , 5, bvaa180	0.4	2
53	Vitamin D3 supplementation improves glycemic control in type 2 diabetic patients: Results from an Italian clinical trial. <i>International Journal for Vitamin and Nutrition Research</i> , <b>2020</b> , 1-10	1.7	2
52	Nutraceutical Approach to Preventing Coronavirus Disease 2019 and Related Complications. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 582556	8.4	2
51	A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effectiveness of a Food Supplement Containing Creatine and D-Ribose Combined with a Physical Exercise Program in Increasing Stress Tolerance in Patients with Ischemic Heart Disease. <i>Nutrients</i> , <b>2019</b> , 11,	6.7	2
50	Canrenone on cardiovascular mortality in congestive heart failure: CanrenOne effects on cardiovascular mortality in patients with congestive heart failure: The COFFEE-IT study. <i>Pharmacological Research</i> , <b>2019</b> , 141, 46-52	10.2	2
49	Ilex paraguariensis, white mulberry and chromium picolinate in patients with pre-diabetes. <i>Phytotherapy Research</i> , <b>2020</b> , 34, 1377-1384	6.7	2

48	Retraction notice to "Evaluation of the positive effects on insulin-resistance and βcell measurements of vildagliptin in addition to metformin in type 2 diabetic patients" [Pharmacol. Res. 73 (2013) 20-26]. <i>Pharmacological Research</i> , <b>2017</b> , 121, 255	10.2	1
47	Subjective effects of a combined lipid-lowering nutraceutical or ezetimibe on well-being and sexual performance in patients with perceived worsening of erectile function during statin treatment: a randomised clinical trial. <i>Nutrafoods</i> , <b>2015</b> , 14, 127-131		1
46	Inhaled insulin: weighing the pros and cons. <i>Lancet Diabetes and Endocrinology</i> , <b>2015</b> , 3, 834-5	18.1	1
45	Glibenclamide and cardio-metabolic risk: a systematic review. <i>International Journal of Diabetes in Developing Countries</i> , <b>2014</b> , 34, 61-68	0.8	1
44	Response to an oral fat load and effects on lipid profile, glycemia and high-sensitivity C-reactive protein after soybean extract consumption. <i>Archives of Medical Science</i> , <b>2018</b> , 14, 760-765	2.9	1
43	Bicarbonate dialysis compared to hemodiafiltration on glycemic excursions in patients with end-stage renal disease with and without type 2 diabetes mellitus. <i>Journal of Diabetes and Its Complications</i> , <b>2015</b> , 29, 1136-41	3.2	1
42	A curious case of hypoglycaemia. <i>Archives of Medical Science</i> , <b>2013</b> , 9, 752-4	2.9	1
41	Difference in incidence of cough induced by imidapril and ramipril: Role of prostaglandin synthesis inhibition. <i>Biomedicine and Aging Pathology</i> , <b>2011</b> , 1, 73-77		1
40	Effect of valsartan on adiponectine, leptin and resistin in hypertensive obese patients. <i>American Journal of Hypertension</i> , <b>2005</b> , 18, A196-A197	2.3	1
39	Glibenclamide plus metformin combination tablets are effective, convenient and well tolerated in the treatment of type 2 diabetes mellitus. <i>Drugs and Therapy Perspectives</i> , <b>2006</b> , 22, 1-6	1.5	1
38	Association between low-molecular weight apolipoprotein(a) isoforms and obesity in Italian women. <i>Obesity</i> , <b>2004</b> , 12, 1322-6		1
37	Risk management in the treatment of type 2 diabetes with pioglitazone. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , <b>2009</b> , 2, 51-60	3.4	1
36	Effects of a nutraceutical combination of monacolin, βryzanol and βaminobutyric acid on lipid profile and C-reactive protein in mice. <i>Archives of Medical Science</i> , <b>2019</b> , 15, 792-796	2.9	1
35	Traditional Markers in Liver Disease. <i>Biomarkers in Disease</i> , <b>2017</b> , 3-22		1
34	Histological Biomarkers of Nonalcoholic Fatty Liver Disease. <i>Biomarkers in Disease</i> , <b>2017</b> , 693-705		1
33	Overview of Biochemical Markers of Bone Metabolism. <i>Biomarkers in Disease</i> , <b>2017</b> , 3-21		1
32	Testing Pharmacological Profiles with Biomarkers Relevant to Cardiovascular Profiles <b>2015</b> , 1-24		1
31	Metabolic Actions of a Supplement of Ilex Paraguariensis (An Extract of the Leaf Standardized to 2% I-Deoxinojirimcina), White Mulberry and Chromium Picolinate in Nondiabetic Subjects with Dysglycemia: A Randomized Trial. <i>Life</i> , <b>2021</b> , 11,	3	1

30	Vascular Cell Adhesion Molecule-1 (VCAM-1) Expression in Liver Disease. <i>Exposure and Health</i> , <b>2016</b> , 1-18.8	0
29	Effects of experimental colitis in rats on incretin levels, inflammatory markers, and enteric neuronal function. <i>Archives of Medical Science</i> , <b>2021</b> , 17, 1087-1092	2.9 0
28	Effects of Oral Administration of Alprazolam and Lorazepam as Hypnotics on Cardiovascular Parameters in Hypertensive Patients. <i>Journal of Clinical Psychopharmacology</i> , <b>2021</b> , 41, 191-195	1.7 0
27	Evaluation of the Effect on Sexual Performance of a Nutraceutical Combination Containing Alpha Lipoic Acid, L. and , Compared to Placebo, Avanafil or a Combination of Nutraceutical Plus Avanafil in Males With Type 2 Diabetes Mellitus With Erectile Dysfunction.. <i>Frontiers in Endocrinology</i> , <b>2022</b> , 13, 847240	5.7 0
26	Retraction notice to "Acarbose on insulin resistance after an oral fat load: a double-blind, placebo controlled study". <i>Journal of Diabetes and Its Complications</i> , <b>2017</b> , 31, 1248	3.2
25	Pharmacotherapy for Obesity <b>2014</b> , 261-277	
24	Diabetes: safety and efficacy of albiglutide-results from two trials. <i>Nature Reviews Endocrinology</i> , <b>2014</b> , 10, 514-6	15.2
23	Retraction notice to "Variation of some inflammatory markers in hypertensive patients after 1 year of olmesartan/amlodipine single-pill combination compared with olmesartan or amlodipine monotherapies": J Am Soc Hypertens 7 (2013) 32-39. <i>Journal of the American Society of Hypertension</i> , <b>2017</b> , 9, 822	
22	Retraction notice to "Enalapril/lercanidipine combination on markers of cardiovascular risk: a randomized study": J Am Soc Hypertens 8 (2014) 422-428. <i>Journal of the American Society of Hypertension</i> , <b>2015</b> , 9, 822	
21	6D.07. <i>Journal of Hypertension</i> , <b>2015</b> , 33, e84	1.9
20	Is it time to implement a standardized oral glucose and fat load test to detect high risk patients? Probably not yet. <i>Atherosclerosis</i> , <b>2015</b> , 243, 346-7	3.1
19	Cardiovascular drugs and mortality in hypertensive patients with atrial fibrillation: evidence of efficacy for a global approach. <i>Hypertension Research</i> , <b>2014</b> , 37, 492-3	4.7
18	Optimizing glycemic control: clinical utility of exenatide prolonged release injection. <i>Research and Reports in Endocrine Disorders</i> , <b>2012</b> , 41	
17	Glimepiride-pioglitazone Hydrochloride in the Treatment of Type 2 Diabetes. <i>Clinical Medicine Therapeutics</i> , <b>2009</b> , 1, CMT.S2016	
16	Re: The influence of statin medications on prostate-specific antigen levels. <i>Journal of the National Cancer Institute</i> , <b>2009</b> , 101, 610; author reply 610-1	9.7
15	11.11 Effect of Valsartan-Amlodipine Combination on Cognitive Function In Elderly Hypertensive Patients. <i>High Blood Pressure and Cardiovascular Prevention</i> , <b>2008</b> , 15, 307-307	2.9
14	Risk management in the treatment of type 2 diabetes with pioglitazone. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , <b>2009</b> , Volume 2, 51-60	3.4
13	Fixed-dose combination rosiglitazone/glimepiride in the treatment of Type 2 diabetes mellitus. <i>Therapy: Open Access in Clinical Medicine</i> , <b>2006</b> , 3, 559-569	

- 12 Effect of benazepril addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. *American Journal of Hypertension*, **2002**, 15, A35 2.3
- 11 Effects of different dihydropyridine calcium antagonists on plasma norepinephrine in essential hypertension. *American Journal of Hypertension*, **2002**, 15, A36 2.3
- 10 Metformin: From Immediate Release to Extended Release Formula, Effectiveness, And Safety in Patients With Chronic Kidney Disease. *European Medical Journal Diabetes*, 70-78 1
- 9 Fixed-dose combination rosiglitazone/glimepiride in the treatment of Type 2 diabetes mellitus. *Therapy: Open Access in Clinical Medicine*, **2006**, 3, 559-569
- 8 EFFECT OF AMLODIPINE-ATORVASTATIN COMBINATION ON FIBRINOLYSIS IN HYPERTENSIVE HYPERCHOLESTEROLEMIC INSULIN-RESISTANT PATIENTS. *Journal of Hypertension*, **2004**, 22, S365 1.9
- 7 Nutraceutical Herbs and Insulin Resistance **2019**, 223-242
- 6 Vascular Cell Adhesion Molecule-1 (VCAM-1) Expression in Liver Disease. *Biomarkers in Disease*, **2017**, 707-717
- 5 Psyllium improves dyslipidaemia, hyperglycaemia and hypertension, while guar gum reduces body weight more rapidly in patients affected by metabolic syndrome following an AHA Step 2 diet. *Mediterranean Journal of Nutrition and Metabolism*, **2009**, 3, 47-54 1.3
- 4 Efficacy and Safety of Ertugliflozin in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease Treated With Metformin and Sulfonylurea. *Journal of the Endocrine Society*, **2021**, 5, A331-A331 0.4
- 3 Testing Pharmacological Profiles with Biomarkers Relevant to Cardiovascular Profiles **2016**, 3-26
- 2 Histological Biomarkers of Nonalcoholic Fatty Liver Disease. *Exposure and Health*, **2016**, 1-13 8.8
- 1 Retraction notice to "Results from a 12 months, randomized, clinical trial comparing an olmesartan/amlodipine single pill combination to olmesartan and amlodipine monotherapies on blood pressure and inflammatin" [European Journal of Pharmaceutical Sciences 51C (2013) 26-33]. *European Journal of Pharmaceutical Sciences*, **2019**, 123, 504 5.1